Health TrialsbyHealthPanel

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

ConditionsLower Gastrointestinal BleedingDiverticular Bleeding
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorNext Biomedical Co., Ltd.

About this trial

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 19 years or older at the time of screening

Patients diagnosed with diverticular bleeding

Disqualifiers

Patients diagnosed with upper gastrointestinal bleeding

Trial design

Design model

Single group

Treatments tested in this trial

  • Nexpowder™

    Device

    Nexpowder™ hemostatic powder

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: Nexpowder Treatment ArmExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Rebleeding rate

30 days after successful endoscopic hemostasis

Time frame
30 days post treatment

Secondary outcomes

1

Hemostasis rate

Hemostasis rate

Time frame
Immediately after the procedure
2

Rebleeding rate

Rebleeding rate

Time frame
7 days post treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Next Biomedical Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: